Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial

BACKGROUND: New anti-tuberculosis regimens that are shorter, simpler, and less toxic than those that are currently available are needed as part of the global effort to address the tuberculosis epidemic. We aimed to investigate the bactericidal activity and safety profile of combinations of bedaquili...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lancet Respir Med
Hauptverfasser: Tweed, Conor D, Dawson, Rodney, Burger, Divan A, Conradie, Almari, Crook, Angela M, Mendel, Carl M, Conradie, Francesca, Diacon, Andreas H, Ntinginya, Nyanda E, Everitt, Daniel E, Haraka, Frederick, Li, Mengchun, van Niekerk, Christo H, Okwera, Alphonse, Rassool, Mohammed S, Reither, Klaus, Sebe, Modulakgotla A, Staples, Suzanne, Variava, Ebrahim, Spigelman, Melvin
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2019
Schlagworte:
Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7641992/
https://ncbi.nlm.nih.gov/pubmed/31732485
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2213-2600(19)30366-2
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge